SU5416 in Treating Patients With Malignant Mesothelioma

Status Completed

Clinical Trial Summary

Phase II trial to study the effectiveness of SU5416 in treating patients who have malignant mesothelioma. SU5416 may stop the growth of malignant mesothelioma by stopping blood flow to the tumor.

Clinical Trial Description

OBJECTIVES:

I. Determine the objective response rate, median and overall survival, and time to progression in patients with unresectable malignant mesothelioma treated with SU5416.

II. Determine the effect of SU5416 on surrogate biologic endpoints, including microvessel density, tissue proliferative index, apoptosis, vascular endothelial growth factor levels, and tumor perfusion measured by MRI in these patients.

III. Determine the toxicity of this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive SU5416 IV over 1 hour twice weekly. Courses repeat every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: Approximately 21-45 patients will be accrued for this study within 18-24 months. ;

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00006014
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Completed
Phase	Phase 2
Start date	August 2000
Completion date	February 2009

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06057935` - A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma	Phase 2
Completed	`NCT00821860` - Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma	Phase 3
Completed	`NCT00075699` - Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma	Phase 3
Completed	`NCT00004033` - Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma	Phase 2
Active, not recruiting	`NCT03678350` - Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery	Phase 1
Recruiting	`NCT02580747` - Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso	Phase 1
Completed	`NCT00398138` - Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma	Phase 1
Completed	`NCT00019825` - Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura	Phase 1
Terminated	`NCT00898547` - Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107
Active, not recruiting	`NCT00030459` - Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma	Phase 2
Completed	`NCT00004183` - Capecitabine in Treating Patients With Malignant Mesothelioma	Phase 2
Completed	`NCT00004920` - Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura	Phase 3
Completed	`NCT00005636` - Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery	Phase 3
Completed	`NCT00004254` - Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed	Phase 2
Completed	`NCT00334594` - Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma	Phase 2
Completed	`NCT01291420` - Dendritic Cell Vaccination for Patients With Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT03852823` - Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours	Phase 1
Active, not recruiting	`NCT01649024` - A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma	Phase 2
Completed	`NCT00513877` - Bortezomib in Treating Patients With Malignant Pleural Mesothelioma	Phase 2
Completed	`NCT00372840` - Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer	N/A